Purpose
The purpose of this document is to communicate that the Company has revised its coverage position for cantharidin (Ycanth) topical solution.
The coverage position for cantharidin (Ycanth), represented by HCPCS code J7354, has been revised from non-covered to medically necessary. This medically necessary coverage position is retroactively effective for dates of service beginning 04/01/2024.
Background
Cantharidin (Ycanth) topical solution is approved by the US Food and Drug Administration (FDA) for the treatment of molluscum contagiosum in adult and pediatric individuals ages 2 years and older.
Coverage Statement
Cantharidin (Ycanth) topical solution is considered medically necessary and, therefore, covered for the treatment of molluscum contagiosum in adult and pediatric individuals ages 2 years and older. Cantharidin (Ycanth) topical solution is administered by a professional provider as a single application to each lesion every three weeks as needed, with no more than two applicators used per session.
Coding
J7354 | Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg) |